Pancreatic cancer may be far more adaptable than its already grim reputation suggests. A new study maps how individual tumor cell populations change over time, uncovering genetic routes that help the disease become more aggressive, resist treatment, and evade the immune system. The findings identify MYC as a potential pressure point for future therapies.
Published October 13 in Nature Genetics, the research was led by scientists at NYU Langone Health and Perlmutter Cancer Center, with collaborators at UC San Diego and Oregon Health and Science University. The paper, “Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression”, examined 443,451 individual cells taken from 62 pancreatic ductal adenocarcinoma tumors.
That cell-by-cell approach matters because a pancreatic tumor is not a uniform mass. Researchers found between two and 11 distinct clones within individual tumors, with genetically related populations behaving in markedly different ways. Some retained the less aggressive “classical” profile, while others shifted toward the more dangerous “basal” state associated with invasion, spread, and poorer treatment responses. The analysis included six patients whose tumors were sampled before and after chemotherapy, offering a glimpse of how treatment may reshape the cellular ecosystem.
The most promising clue involved MYC, a gene that was unusually active in aggressive cancer populations. In laboratory experiments, blocking MYC caused basal pancreatic cancer cells to move toward the less aggressive classical state. The altered cells also became more visible to immune cells, suggesting that MYC inhibition might affect both tumor behavior and the cancer’s ability to hide from immune attack. NYU Langone’s summary of the work describes the result as a possible way to restrain tumor evolution rather than simply attack a fixed cancer state.
The study also helps explain why immunotherapy has had limited success against pancreatic cancer. Certain tumor clones showed increased activity of TIGIT, a gene associated with immune suppression, while displaying lower activity of PD1. That combination could help tumors escape detection and may partly explain why treatments aimed at the PD-1 pathway have struggled in pancreatic ductal adenocarcinoma.
This is not yet a treatment breakthrough: the MYC experiments were conducted in the laboratory, and the researchers say additional work is needed before the approach can be tested as a dependable therapy. Still, the findings support a shift toward tracking the changing populations inside a tumor instead of treating pancreatic cancer as a single, stable disease. Clinical trials involving MYC- or TIGIT-targeting drugs are already being investigated in pancreatic cancer and other cancers, giving the new molecular map a possible route toward practical testing.
